TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly: "I just think this is a decent level ... Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.

Eli Lilly & Co. said Tuesday it’s cutting the ... The move came just days after a regulatory ruling that there’s no longer a shortage of weight-loss drugs that had allowed for alternatives ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...